Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022. The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store?
Biogen Inc. (BIIB) closed at $239.30 in the latest trading session, marking a +1.11% move from the prior day.
Are some major acquisitions on the way in the biopharmaceutical industry this year? That remains to be seen. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen.